Orchestra BioMed Holdings, Inc.
NASDAQ:OBIOBiotechnology
+$0.05 today
- Market cap
- $587.14M
- Beta
- 0.50
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.42
Volume 1.20M
Average 0.22M
OBIO Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Orchestra BioMed Holdings, Inc.NASDAQ: OBIO
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 109.4% from a year ago
Short-term investments stood at $66.03M at the end of Q1 FY2026, up 109.4% from a year earlier and down 8.1% from the prior quarter. Over 3 fiscal years it compounded at +3.9% a year.
Context
- Short-term investments amounted to 65.6% of total assets at the end of Q1 FY2026, up 12.2 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +109.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 71.82M USD
- Year-over-year change
- +61.2%
- 4-year CAGR
- +194.3%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71.82M | +61.2% |
| FY2024 | 2024-12-31 | 44.55M | -21.9% |
| FY2023 | 2023-12-31 | 57.04M | -10.9% |
| FY2022 | 2022-12-31 | 64M | +6580.7% |
| FY2021 | 2021-12-31 | 958K | — |
Short-term Investments vs competitors
How OBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +109.4% is the 2nd highest of 7, against a peer median of -22.1%.
- Short-term investments amounts to 65.6% of total assets for OBIO, versus a peer median of 52.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $128.85M USD | -3.2% | -8.6% | 40.9% | |
| Mar 2026 | $121.05M USD | +267.9% | +20.7% | 63.1% | |
| Mar 2026 | $105.57M USD | -41.0% | -12.5% | 70.9% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $80.64M USD | — | — | 55.3% |
| Mar 2026 | $66.03M USD | +109.4% | +3.9% | 65.6% | |
| Mar 2026 | $59.8M USD | +1.7% | -26.5% | 50.0% | |
| Mar 2026 | $57.01M USD | — | — | 57.1% | |
| Mar 2026 | $35.25M USD | -62.0% | — | 54.8% | |
| Dec 2025 | €0 EUR | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding OBIO) | — | -22.1% | -10.5% | 52.4% | |
Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9.94M | 19.78M | 30.56M | 22.26M | 34.69M |
| Short-term Investments | 958K | 64M | 57.04M | 44.55M | 71.82M |
| Net Receivables | 121K | 96K | 99K | 92K | 95K |
| Inventory | 68K | 276K | 146K | 173K | 310K |
| Other Current Assets | 0 | 533K | 1.27M | 2.09M | 994K |
| Total Current Assets | 11.32M | 84.69M | 89.11M | 69.17M | 107.91M |
| Property, Plant & Equipment (Net) | 1.12M | 3.68M | 2.83M | 3.49M | 3.21M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 398K | 2.5M | 2.5M | 2.5M | 2.5M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 690K | 4.71M | 769K | 1.02M | 1.24M |
| Total Non-current Assets | 2.21M | 10.88M | 6.1M | 7M | 6.95M |
| Total Assets | 13.53M | 95.57M | 95.21M | 76.17M | 114.86M |
| Account Payables | 2.03M | 3.97M | 2.9M | 5.13M | 6.1M |
| Short-term Debt | 2M | 0 | 0 | 0 | 751K |
| Tax Payables | 1K | 0 | 0 | 0 | 0 |
| Deferred Revenue | 5.54M | 6.44M | 2.51M | 4.44M | 0 |
| Other Current Liabilities | 2M | 4.57M | 2.66M | 2.61M | 9.89M |
| Total Current Liabilities | 12.24M | 18.57M | 11.21M | 16.21M | 16.74M |
| Long-term Debt | 3.67M | 9.49M | 0 | 14.29M | 936K |
| Deferred Tax Liabilities | 0 | 0 | (14.92M) | 0 | 0 |
| Deferred Revenue (Non-current) | 16.86M | 13.1M | 14.92M | 10.99M | 0 |
| Other Non-current Liabilities | 51.99M | 196K | 14.92M | 40K | 33.81M |
| Total Non-current Liabilities | 72.52M | 24.47M | 15.96M | 27.01M | 34.74M |
| Total Liabilities | 84.76M | 43.04M | 27.17M | 43.22M | 51.48M |
| Common Stock | 160M | 2K | 4K | 4K | 6K |
| Retained Earnings | (166.13M) | (199.73M) | (248.85M) | (309.88M) | (362.58M) |
| Accumulated OCI | (211.45M) | (8K) | (10K) | 52K | 60K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (71.23M) | 52.53M | 68.04M | 32.96M | 63.38M |
| Total Debt | 5.67M | 11.87M | 1.69M | 16.53M | 1.69M |
| Net Debt | (4.27M) | (7.91M) | (28.87M) | (5.73M) | (33M) |
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Intrinsic Alpha fair value
Locked
Current Price
$7.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.